These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9635244)

  • 1. In vitro evaluation of cefpirome: an Australasian study of isolates from intensive care unit and hematology/oncology patients. The Cefpirome Study Group.
    Fernandes C; Pritchard R; Morris A; Benn R
    Diagn Microbiol Infect Dis; 1998 Jul; 31(3):493-5. PubMed ID: 9635244
    [No Abstract]   [Full Text] [Related]  

  • 2. Cefpirome: epidemiological survey in intensive care units and hematological units in The Netherlands. The Dutch Study Group.
    Hoogkamp-Korstanje JA; Verduyn Lunel F; Meis JF
    Diagn Microbiol Infect Dis; 1998 Jul; 31(3):489-91. PubMed ID: 9635243
    [No Abstract]   [Full Text] [Related]  

  • 3. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
    Spencer RC
    Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology and sensitivity of 8625 ICU and hematology/oncology bacterial isolates in Europe. International Study Group.
    Verbist L
    Scand J Infect Dis Suppl; 1993; 91():14-24. PubMed ID: 8290899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology units. Belgian Multicentre Study Group.
    Piérard D; Emmerechts K; Lauwers S
    J Antimicrob Chemother; 1998 Apr; 41(4):443-50. PubMed ID: 9598775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and antibiotic sensitivity of Danish versus other European bacterial isolates from intensive care and hematology/oncology units.
    Fomsgaard A; Høiby N; Friis HM; Gahrn-Hansen B; Kolmos HJ; Schouenborg P; Korsager B; Tvede M; Gutschik E; Bremmelgaard A
    Eur J Clin Microbiol Infect Dis; 1995 Apr; 14(4):275-81. PubMed ID: 7649189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of antimicrobial use and resistance of bacterial isolates in a haematology ward and an intensive care unit.
    Lang A; De Fina G; Meyer R; Aschbacher R; Rizza F; Mayr O; Casini M
    Eur J Clin Microbiol Infect Dis; 2001 Sep; 20(9):657-60. PubMed ID: 11714050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of cefpirome and other antimicrobial agents against isolates from cancer patients.
    Rolston K; Alvarez ME; Hoy JF; LeBlanc B; Ho DH; Bodey GP
    Chemotherapy; 1986; 32(4):344-51. PubMed ID: 3731920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of ceftobiprole against Gram-positive and Gram-negative bacteria isolated from humans and animals.
    Silva N; Radhouani H; Gonçalves A; Araújo C; Rodrigues J; Igrejas G; Poeta P
    J Antimicrob Chemother; 2010 Apr; 65(4):801-3. PubMed ID: 20110342
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro activity of cefpirome (HR810) against antibiotic-resistant gram-positive and gram-negative bacteria including organisms with inducible resistance.
    Murray PR; Niles AC
    Diagn Microbiol Infect Dis; 1986 Jan; 4(1):53-63. PubMed ID: 3632921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing of microbial sensitivity to cephalosporin.
    Dorobăţ O; Bărbulescu C; Păun L
    Arch Roum Pathol Exp Microbiol; 1989; 48(2):185-8. PubMed ID: 2634370
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effectiveness of cefpirome in the treatment of complicated infections of the upper and lower urinary tracts].
    Derevianko II; Kotliarova GA; Kondrat'eva EM; Khodyreva LA; Siniukhin VN
    Antibiot Khimioter; 1996; 41(12):30-3. PubMed ID: 9124983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of cefpirome against microorganisms isolated in haematology, oncology and intensive care units in Switzerland.
    Liassine N; Bille J; Breer C; Frei R; Wüst J; Auckenthaler R
    Scand J Infect Dis; 1997; 29(6):615-21. PubMed ID: 9571744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998.
    Fluit AC; Verhoef J; Schmitz FJ;
    Eur J Clin Microbiol Infect Dis; 2001 Sep; 20(9):617-25. PubMed ID: 11714042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic resistance--experience in a tertiary care hospital in south India.
    Subbalaxmi MV; Lakshmi V; Lavanya V
    J Assoc Physicians India; 2010 Dec; 58 Suppl():18-22. PubMed ID: 21568007
    [No Abstract]   [Full Text] [Related]  

  • 16. First point prevalence survey of nosocomial infections in the intensive care units of a tertiary care hospital in Albania.
    Faria S; Sodano L; Dauri M; Sabato AF; Gjata A; Kito I; Llazo E; Bilaj A; Mertiraj O; Schinaia N;
    J Hosp Infect; 2008 May; 69(1):95-7. PubMed ID: 18346815
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital.
    Platsouka E; Zissis NP; Constantoulaki S; Paniara O
    J Chemother; 1997 Oct; 9(5):336-40. PubMed ID: 9373788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative activities in vitro of augmentin (amoxycillin/clavulanic acid) and oral cephalosporins.
    Griffin KE; Cooper CE; Slocombe B
    J Chemother; 1989 Jul; 1(4 Suppl):71-3. PubMed ID: 16312309
    [No Abstract]   [Full Text] [Related]  

  • 19. [Activity of cefpirome against bacteria isolated from hospitalized patients].
    Fernández A; Herran I; de Mier C; Marcenac FM
    Medicina (B Aires); 1989; 49(4):373-8. PubMed ID: 2487748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic cycling to decrease bacterial antibiotic resistance: a 5-year experience on a bone marrow transplant unit.
    Cadena J; Taboada CA; Burgess DS; Ma JZ; Lewis JS; Freytes CO; Patterson JE
    Bone Marrow Transplant; 2007 Jul; 40(2):151-5. PubMed ID: 17530005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.